Fort Worth, Texas (April 2, 2015) – Virbac Corporation today announced the promotions of three individuals, Naomi Potts, Bryan Armstrong and Mary Jo McNeily to Sales Director Roles. In these new roles, they will report directly to Jim Van Proosdy, Vice President of Sales for Virbac U.S.

Fort Worth, Texas (January 5, 2015) – Virbac announces the successful closing, on January 2^nd, of its agreement with Eli Lilly and Company to acquire two major parasiticides for dogs in the United States: SENTINEL^® FLAVOR TABS^® and SENTINEL^® SPECTRUM^®, previously marketed by Novartis Animal Health.

Fort Worth, Texas (October 27, 2014) – Virbac Corporation today announced that it has entered into an agreement with Eli Lilly and Company to acquire major U.S. veterinary products currently marketed by Novartis Animal Health. Eli Lilly has agreed to divest these U.S. assets in connection with the U.S. Federal Trade Commission’s review of Eli Lilly’s pending acquisition of Novartis Animal Health worldwide.

Fort Worth, Texas (July 15, 2014) – Virbac Corporation today announced that Dr. Alan Taylor has been named Vice President of Business Development, effective July 14, 2014. In this role, Dr. Taylor will be responsible for generating external growth for Virbac North America and the Commonwealth Countries, through the acquisition or licensing-in of new products, and through the merger and acquisitions of third party companies. Additionally, he will support the R&D internal organization through the licensing-in of opportunities of selected new actives or new technologies that could be further developed internally.

Fort Worth, Texas (March 10, 2014) – Virbac Corporation today announced that Paul Hays has been promoted to President and CEO of North America, effective April 1, 2014, succeeding Dr. Erik Martinez. In his new role, Hays will oversee all corporate functions for Virbac North America and be responsible for the growth and profitability of both U.S. and Canadian operations.